Divalproex vs. Lamotrigine for Bipolar Disorder

Tuscaloosa Research & Education Advancement Corporation

Status: Terminated

Conditions: Bipolar Disorder

Study type: Observational

Funder types: Other

Identifiers

NCT00451542

0063

Details and patient eligibility

About

This study is a retrospective chart review of patients treated for bipolar disorder at the TVAMC in the past four years cross-referenced with the electronic pharmacy file for having received a prescription of divalproex or lamotrigine.

Full description

The primary objective of the study is to assess the long-term outcome in bipolar patients treated with divalproex versus lamotrigine in a retrospective chart review of veterans as measured by time to relapse into any significant mood episode (i.e. mania or depression). The primary hypothesis is that bipolar patients will demonstrate significantly greater time to relapse in those treated with divalproex compared to those treated with lamotrigine. The secondary objective of the study is to assess the safety and relative tolerability of divalproex and lamotrigine in this population based on discontinuation due to side or adverse effect.

Enrollment: 1,000 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Bipolar I or Bipolar II disorder
• Prescription of divalproex (any formulation except for Depakene/valproic acid) or lamotrigine in the electronic pharmacy profile.
• Age 19 or older
• Demonstrated stability for at least 4 weeks on an adequate dose of each medication (at least 50mg/d lamotrigine or 15mg/kg/day divalproex).
• Treatment at the TVAMC for at least 6 months following the prescription of divalproex or lamotrigine.

Exclusion criteria

• Primary diagnosis of schizoaffective or schizophrenia during the evaluation period.
• Prescription of divalproex and lamotrigine given concurrently during the observation period.
• History of Dementia or cognitive disorders